ACRS - Aclaris Therapeutics Inc
IEX Last Trade
1.18
0.010 0.847%
Share volume: 170,634
Last Updated: Fri 30 Aug 2024 09:59:43 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.17
0.01
0.86%
Fundamental analysis
20%
Profitability
0%
Dept financing
7%
Liquidity
75%
Performance
30%
Performance
5 Days
-2.48%
1 Month
-9.92%
3 Months
12.38%
6 Months
-0.84%
1 Year
-84.27%
2 Year
-92.73%
Key data
Stock price
$1.18
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.59 - $8.28
52 WEEK CHANGE
-$0.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Neal Walker
Region: US
Website: https://www.aclaristx.com/
Employees: 62
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.aclaristx.com/
Employees: 62
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Recent news